Sanofi (NASDAQ: SNY) Stock Competitors & Peer Comparison
See SNY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SNY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SNY | $40.07 | -0.32% | 96.6B | 8.76 | $4.59 | +6.03% |
| LLY | $1,179.27 | -0.79% | 1.1T | 37.15 | $31.49 | +0.57% |
| JNJ | $261.44 | +1.16% | 618B | 23.90 | $10.73 | +2.03% |
| ABBV | $276.47 | +1.88% | 481.4B | 26.74 | $10.19 | +2.47% |
| MRK | $145.60 | +1.97% | 351.7B | 44.36 | $3.21 | +2.32% |
| NVS | $143.75 | +0.33% | 272B | 16.47 | $8.69 | +3.30% |
| AZN | $159.20 | -0.57% | 246.2B | 17.14 | $9.26 | +2.03% |
| AMGN | $414.87 | +0.43% | 219.9B | 18.21 | $22.37 | +2.39% |
| GILD | $151.17 | +2.94% | 182.4B | -377.18 | -$0.39 | +2.16% |
| NVO | $38.64 | +0.99% | 169.4B | 9.49 | $4.02 | +4.66% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
SNY vs LLY Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while LLY trades at $1,179.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas LLY's P/E ratio is 37.15. In terms of profitability, SNY's ROE is +0.06%, compared to LLY's ROE of +0.93%. Regarding short-term risk, SNY is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for SNY.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
SNY vs JNJ Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, JNJ has a market cap of 618B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while JNJ trades at $261.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas JNJ's P/E ratio is 23.90. In terms of profitability, SNY's ROE is +0.06%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, SNY is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for SNY.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
SNY vs ABBV Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, ABBV has a market cap of 481.4B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while ABBV trades at $276.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas ABBV's P/E ratio is 26.74. In terms of profitability, SNY's ROE is +0.06%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, SNY is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for SNY.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
SNY vs MRK Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, MRK has a market cap of 351.7B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while MRK trades at $145.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas MRK's P/E ratio is 44.36. In terms of profitability, SNY's ROE is +0.06%, compared to MRK's ROE of +0.07%. Regarding short-term risk, SNY is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for SNY.Check MRK's competition here
Novartis AG (NYSE: NVS)
SNY vs NVS Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, NVS has a market cap of 272B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while NVS trades at $143.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas NVS's P/E ratio is 16.47. In terms of profitability, SNY's ROE is +0.06%, compared to NVS's ROE of +0.30%. Regarding short-term risk, SNY is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for SNY.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
SNY vs AZN Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, AZN has a market cap of 246.2B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while AZN trades at $159.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas AZN's P/E ratio is 17.14. In terms of profitability, SNY's ROE is +0.06%, compared to AZN's ROE of +0.22%. Regarding short-term risk, SNY is similarly volatile compared to AZN. This indicates similar risk in terms of short-term price fluctuations for SNY.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
SNY vs AMGN Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, AMGN has a market cap of 219.9B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while AMGN trades at $414.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas AMGN's P/E ratio is 18.21. In terms of profitability, SNY's ROE is +0.06%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, SNY is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for SNY.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
SNY vs GILD Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, GILD has a market cap of 182.4B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while GILD trades at $151.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas GILD's P/E ratio is -377.18. In terms of profitability, SNY's ROE is +0.06%, compared to GILD's ROE of -0.16%. Regarding short-term risk, SNY is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for SNY.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
SNY vs NVO Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, NVO has a market cap of 169.4B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while NVO trades at $38.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas NVO's P/E ratio is 9.49. In terms of profitability, SNY's ROE is +0.06%, compared to NVO's ROE of +0.59%. Regarding short-term risk, SNY is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for SNY.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
SNY vs PFE Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, PFE has a market cap of 158.7B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while PFE trades at $28.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas PFE's P/E ratio is 9.13. In terms of profitability, SNY's ROE is +0.06%, compared to PFE's ROE of +0.05%. Regarding short-term risk, SNY is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for SNY.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
SNY vs BMY Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, BMY has a market cap of 121.7B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while BMY trades at $59.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas BMY's P/E ratio is 10.04. In terms of profitability, SNY's ROE is +0.06%, compared to BMY's ROE of +0.47%. Regarding short-term risk, SNY is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for SNY.Check BMY's competition here
GSK plc (NYSE: GSK)
SNY vs GSK Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, GSK has a market cap of 93.2B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while GSK trades at $46.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas GSK's P/E ratio is 10.05. In terms of profitability, SNY's ROE is +0.06%, compared to GSK's ROE of +0.24%. Regarding short-term risk, SNY is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for SNY.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
SNY vs BIIB Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, BIIB has a market cap of 32.3B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while BIIB trades at $225.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas BIIB's P/E ratio is 13.79. In terms of profitability, SNY's ROE is +0.06%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, SNY is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for SNY.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
SNY vs HZNP Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas HZNP's P/E ratio is 61.86. In terms of profitability, SNY's ROE is +0.06%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, SNY is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for SNY.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
SNY vs GRFS Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, GRFS has a market cap of 6.3B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while GRFS trades at $7.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas GRFS's P/E ratio is 8.51. In terms of profitability, SNY's ROE is +0.06%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, SNY is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for SNY.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
SNY vs OGN Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while OGN trades at $13.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas OGN's P/E ratio is 4.11. In terms of profitability, SNY's ROE is +0.06%, compared to OGN's ROE of +0.23%. Regarding short-term risk, SNY is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for SNY.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
SNY vs AMRN Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, AMRN has a market cap of 248M. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while AMRN trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas AMRN's P/E ratio is -119.90. In terms of profitability, SNY's ROE is +0.06%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, SNY is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for SNY.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
SNY vs MIRA Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, MIRA has a market cap of 29.5M. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while MIRA trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas MIRA's P/E ratio is -0.48. In terms of profitability, SNY's ROE is +0.06%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, SNY is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for SNY.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
SNY vs SCLX Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, SCLX has a market cap of 25.1M. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while SCLX trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas SCLX's P/E ratio is -0.08. In terms of profitability, SNY's ROE is +0.06%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, SNY is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for SNY.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
SNY vs SCLXW Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, SCLXW has a market cap of 21M. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while SCLXW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas SCLXW's P/E ratio is N/A. In terms of profitability, SNY's ROE is +0.06%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, SNY is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for SNY.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
SNY vs BDSIW Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, SNY's ROE is +0.06%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, SNY is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for SNY.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
SNY vs CRXT Comparison October 2026
Sanofi (NASDAQ: SNY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SNY stands at 96.6B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, SNY is priced at $40.07 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SNY currently has a P/E ratio of 8.76, whereas CRXT's P/E ratio is -0.02. In terms of profitability, SNY's ROE is +0.06%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, SNY is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for SNY.Check CRXT's competition here